^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    pan-KRAS inhibitor

    Related drugs:
    2d
    TQB3205-I-01: Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov)
    P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab)
    30d
    A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation (clinicaltrials.gov)
    P1, N=145, Recruiting, Kestrel Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    1m
    Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=156, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    1m
    A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation (clinicaltrials.gov)
    P1, N=145, Not yet recruiting, Kestrel Therapeutics, Inc.
    New P1 trial • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    2ms
    Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants. (PubMed, Cancer Discov)
    We discovered BBO-11818, a potent and selective noncovalent KRAS inhibitor with activity against multiple KRAS mutants in both the active (ON) and inactive (OFF) states. BBO-11818 addresses the need for KRAS inhibitors targeting clinically relevant mutants such as KRASG12D and KRASG12V, either as monotherapy or in combination.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • KRAS G12C • KRAS G12D
    2ms
    J5Q-OX-JRDA: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G12 • KRAS G12S • KRAS G13
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    2ms
    Study of AUBE00 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Chugai Pharmaceutical | N=100 --> 130 | Trial completion date: Jun 2030 --> Dec 2029 | Trial primary completion date: Jun 2030 --> Dec 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab)
    2ms
    TLN-372-2501: A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advanced KRAS Mutant Solid Cancers (2025-523086-22-00)
    P1/2, N=20, Recruiting, Treeline Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab)
    2ms
    A study of TLN-372 in Patients with Advanced KRAS Mutant Solid Tumors. (ACTRN12626000207314)
    P1, N=50, Not yet recruiting, Treeline Biosciences, Inc.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    2ms
    20240031: AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors (2025-521707-48-00)
    P1, N=135, Recruiting, Amgen Inc.
    New P1 trial
    2ms
    TLN-372-2501: A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advanced KRAS Mutant Solid Cancers (2025-523086-22-00)
    P1/2, N=20, Not yet recruiting, Treeline Biosciences Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab)